FDA group model in R [Two-Stage / GS Designs]

posted by VStus – Poland, 2016-10-20 15:57 (2742 d 08:49 ago) – Posting: # 16745
Views: 34,344

Dear Maestro,

❝ I actually lost a bit track of this discussion and I am not exactly sure what the comparisons try to achieve?!?


I'm sorry for confusion. I accept that I for sure may understood this topic completely wrong. I just wanted to address Myttiry's issue of non-similar results between R's lm() and WinNonlin in assessment of the FDA group model 1 and 2 for unbalanced dataset.

I don't have access to SAS or WinNonlin, but I have some study reports assessed via SAS using FDA's group model 1 and 2. So, in regards to Point Estimates, 90% CIs, F and P values for:
FDA Group 1 Group*Treat #Treat:Group in my R output
FDA Group 2
- Treat #Drug in my R output
- Per(Group) # group:prd in my R output
- Subj(Group*Seq) # seq:subj in R
lm() provides same results as PROC GLM

If Russian Authorities require an additional assessment using a group model, R output should be ok. So as PHX, if PE and 90%CI are not calculated using FDA Group Model 1.

Regards,
VStus

Complete thread:

UA Flag
Activity
 Admin contact
22,993 posts in 4,828 threads, 1,656 registered users;
54 visitors (0 registered, 54 guests [including 3 identified bots]).
Forum time: 00:47 CEST (Europe/Vienna)

If you don’t like something change it;
if you can’t change it, change the way you think about it.    Mary Engelbreit

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5